Kinetics of Yohimbine in Humans to Explore Sex and CYP2D6 Genotype Interactions

The study is designed as an open-label, single-dose protocol with four study arms based on sex and CYP2D6 genotype. A single oral dose of yohimbine and ¹³C₃-caffeine will be administered with 240 ml of still water under overnight fasting conditions.

A total of 19 blood samples will be collected at defined time points (baseline; 10; 20; 30; 40; 50; 60; 70; 80; 90; 100; 110 min; 2; 3; 4; 6; 8; 10; 24 h). At each time point, 4.9 mL of blood will be drawn for plasma separation to determine yohimbine, the primary metabolite 11-OH-yohimbine and 13C₃-caffeine with associated CYP1A2 dependent metabolites. One additional blood sample (EDTA tube) for potential future genetic analysis, will be collected together with the baseline kinetic samples.

For each participant, a total of approximately 98 mL of blood will be collected during the kinetic visits and an additional 12 mL during the screening visit.

Following the administration of yohimbine and 13C3-caffeine, participants will consume 200 mL of sparkling water every hour to stimulate gastrointestinal peristalsis facilitate substance transport. Two hours post-administration, participants may have a cup of tea or coffee, while a standardized meal will be served four hours after dosing.

Urine samples will be collected over 24 hours in three intervals (0-4 h, 5-10 h, 11-24 h). Blood pressure and heart rate monitoring will be conducted during the initial four hours and participants will remain in the Clinical Research Unit of the Institute of Pharmacology for the first 10 hours post-administration. At 24 hours post-dosing, participants will return to the Clinical Research Unit for the final scheduled blood collection and to provide their last urine sample (11-24 h).

Inclusion criteria

• individuals of both biological sexes, assigned as women or men at birth
• age: ≥ 18 and ≤ 40 years
• possesses the ability to understand the study purpose and design
• contractually capable and provides signed informed consent form
• in good general health or with mild and/or well-managed conditions such as allergies, asthma, hypertension or orthopedic diseases
• taking no more than three chronic medications
• individuals classified as either extensive metabolizers (EM) or poor metabolizers (PM) based on their CYP2D6 genotype:

Extensive Metabolizers (EM):

homozygous for CYP2D6 *1,CYP2D6 *2, CYP2D6 *35, or heterozygous combination of any of these alleles

Poor Metabolizers (PM):

homozygous for CYP2D6 *3, CYP2D6 *4, CYP2D6 *5, CYP2D6 *6, or heterozygous combination of any of these alleles

Exclusion criteria

• BMI > 30 kg/m2 and < 18 kg/m2
• body weight < 48 kg
• women: known pregnancy or lactation period; positive urine pregnancy test at screening or kinetic visit
• men: hemoglobin < 13 g/dl (8,07 mmol/l) women: hemoglobin < 12 g/dl (7,45 mmol/l)
• elevated liver function tests (1 or more of ALAT, ASAT, yGT, Bilirubin > 2x ULN)
• reduced renal function (eGFRMDRD < 60 mL/min/1,7 m2)
• QTcF > 450 ms in screening ECG
• current or recent psychiatric disorders requiring treatment including depression, bipolar disorder, schizophrenia, psychosis or severe anxiety disorders
• drug dependency at the time of visit
• use of recreational drugs more than twice a week
• any known hypersensitivity or allergic reactions to yohimbine or caffeine
• history of severe hypersensitivity reactions and/or anaphylaxis
• poor venous conditions that make it impossible to place a peripheral venous catheter and regularly draw blood through it

o) intake of drugs interfering with CYP2D6 and/or CYP1A2 during the past seven days p) intake of yohimbine within 48 hours and caffeine within 16 hours prior to study participation q) engagement in extreme physical activity within 48 hours prior to study participation